Afleveringen
-
Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.
-
Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.
-
Zijn er afleveringen die ontbreken?
-
Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.
-
Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.
-
Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.
-
What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.
-
Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.
-
David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.
-
Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.
-
Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.
-
Thomas Zilli and Pierre Blanchard discuss this topic from Lugano.
-
Jason Efstathiou and Piet Ost discuss the data for and against this approach.
-
Alison Birtle describes adjuvant chemotherapy in bladder cancer.
-
Daniel Goldstein describes his work on this issue.
-
In this second part, Matt Galsky describes the OS signal data. We also look into the future.
-
Tom, Brian and Matt Galsky review the screening component of this study, presented at EAU24.
-
Michiel Van der Heijden explores the role of radiotherapy and other neoadjuvant and other neoadjuvant combinations to prevent the need for surgery.
-
FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.
- Laat meer zien